GIC-Backed Chinese Biopharma Firm CStone Raises $284M In HK IPO

CStone Pharmaceuticals, a Chinese clinical-stage biopharmaceutical company, has raised about HK$2.23 billion (US$284.09 million) in an initial public offering on the Hong Kong stock exchange on Tuesday, which makes it become the sixth pre-profit Chinese biotech company to float shares in the financial hub.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in